Tseng, Cheng-HaoCheng-HaoTsengChen, Tzu-HawTzu-HawChenWu, Jia-LingJia-LingWuLee, Teng-YuTeng-YuLeeBorghi, John AJohn ABorghiJAW-TOWN LINNguyen, Mindie HMindie HNguyenHsu, Yao-ChunYao-ChunHsu2023-08-312023-08-312023-0125895559https://www.scopus.com/record/display.uri?eid=2-s2.0-85142499471&origin=resultslist&sort=plf-fhttps://scholars.lib.ntu.edu.tw/handle/123456789/634864The risk of serious clinical outcomes following cessation of nucleos(t)ide analogues (NUCs) in individuals with chronic hepatitis B remains poorly characterized. This systematic review and meta-analysis aimed to evaluate current literature on this issue.enALT, alanine transaminase; CHB, chronic hepatitis B; Chronic hepatitis B; ETV, entecavir; HBV, hepatitis B virus; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; NUC, nucleos(t)ide analogues; PT, prothrombin time; TDF, tenofovir disoproxil fumarate; finite therapy; nucleos(t)ide analogue; outcome researchSerious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysisjournal article10.1016/j.jhepr.2022.100617364669892-s2.0-85142499471https://api.elsevier.com/content/abstract/scopus_id/85142499471